Zevra Therapeutics, Inc. ZVRA Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Zevra Therapeutics, Inc.'s pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Zevra Therapeutics, Inc.'s pre-tax income?
- Zevra Therapeutics, Inc. (ZVRA) reported pre-tax income of $44.8M in Q1 2026.
- How has Zevra Therapeutics, Inc.'s pre-tax income changed year-over-year?
- Zevra Therapeutics, Inc.'s pre-tax income increased by 2437.2% year-over-year, from -$1.92M to $44.8M.
- What is the long-term trend for Zevra Therapeutics, Inc.'s pre-tax income?
- Over 3 years (2021 to 2025), Zevra Therapeutics, Inc.'s pre-tax income has grown at a 116.7% compound annual growth rate (CAGR), from -$8.52M to $86.68M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.